Payment overview · 2025
General Payments
$2,242.86
120 reported records · 18 companies
Healthcare provider profile · identity verified
Billy Reid Mcbay, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CONWAY, AR · NPI 1659340826
Verified facts
What the public records show
CMS Open Payments records show Billy Reid Mcbay, M.D. received $2,242.86 in general payments during 2025 across 120 reported records.
ABBVIE INC. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $554.69 | 24.7% | 34 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $460.69 | 20.5% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $400.33 | 17.9% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.89 | 7.9% | 8 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $115.99 | 5.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.25 | 3.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.94 | 3.3% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.60 | 3.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.11 | 3.0% | 3 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $49.38 | 2.2% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $35.42 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.48 | 1.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.76 | 1.2% | 5 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.83 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.39 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.99 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.87 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,242.86 | 120 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $460.69 | 21 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $260.66 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $228.17 | 15 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $186.91 | 11 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $161.51 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.90 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $115.99 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $99.13 | 4 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $85.48 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.25 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.25 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.94 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.36 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.76 | 3 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $49.44 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.14 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $35.42 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.10 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.76 | 5 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $10.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 64 |
| Gabapentin | Gabapentin | 248 | 55 |
| Losartan Potassium | Losartan Potassium | 242 | 54 |
| Omeprazole | Omeprazole | 240 | 55 |
| Clonazepam | Clonazepam | 229 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 44 |
| Alprazolam | Alprazolam | 195 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 145 | 29 |
| Furosemide | Furosemide | 143 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 26 |
| Lisinopril | Lisinopril | 137 | 35 |
| Trazodone Hcl | Trazodone Hcl | 133 | 30 |
| Pregabalin | Pregabalin | 126 | 26 |
| Tramadol Hcl | Tramadol Hcl | 121 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 27 |
| Metformin Hcl | Metformin Hcl | 113 | 27 |
| Buspirone Hcl | Buspirone Hcl | 111 | 24 |
| Mounjaro | Tirzepatide | 107 | 20 |
| Ozempic | Semaglutide | 106 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 90 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 20 |
| Meloxicam | Meloxicam | 86 | 21 |
| Potassium Chloride | Potassium Chloride | 84 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 15 |
| Aripiprazole | Aripiprazole | 77 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Sertraline Hcl | Sertraline Hcl | 71 | 14 |
| Carvedilol | Carvedilol | 68 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 13 |
| Simvastatin | Simvastatin | 66 | 15 |
| Atenolol | Atenolol | 63 | 16 |
| Azithromycin | Azithromycin | 63 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 17 |
| Methylprednisolone | Methylprednisolone | 53 | 39 |
| Promethazine Hcl | Promethazine Hcl | 52 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 51 | 11 |
| Eszopiclone | Eszopiclone | 48 | 11 |
| Glipizide | Glipizide | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Famotidine | Famotidine | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Linzess | Linaclotide | 38 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 24 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Prednisone | Prednisone | 33 | 11 |
| Diazepam | Diazepam | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Estradiol | Estradiol | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,242.86 · 120 records | ABBVIE INC. | ACTHAR, AIRSUPRA, Actemra, Bimzelx, CAPLYTA, ENBREL, EVENITY, FARXIGA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, Kineret, LOREEV XR, NURTEC ODT, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, TALTZ, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XELJANZ, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error